Peri-Transplant Inflammation and Long-Term Diabetes Outcomes Were Not Impacted by Either Etanercept or Alpha-1-Antitrypsin Treatment in Islet Autotransplant Recipients.

"Conflict of Interest MB declares research support from Dexcom and Viacyte; consulting/DSMB membership with Vertex, Insulet, and consulting for Emerging Therapy Solutions. BJH holds equity in and serves as a paid executive officer and director of Diabetes Fee, Inc., a company that may commercially benefit from the results of this research. This interest has been reviewed and managed by the University of Minnesota in accordance with its Conflict of Interest policies. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."

"This study was funded by National Institute of Health grant number R01DK109914 (PI Bellin) and grant number NIDDK T32 DK065519. This research was also supported by the National Institutes of Health’s National Center for Advancing Translational Sciences, grant UL1TR002494 as well as National Institute of Health grant number DK 057846 and grant number DK129523 and DoD grant number W81XWH-18-1-0687."

"Informed consent was obtained from all participants before screening. The study protocol was reviewed and approved by the University of Minnesota’s Institutional Review Board. This study was performed under an Investigational New Drug Application (IND #119828) from the Food and Drug Administration and registered on clinicaltrials.gov (NCT#02713997)."